CBIOCRESCENT BIOPHARMA, INC.同业对比
CRESCENT BIOPHARMA, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CBIO本股 | $503M#7 | — | 3.1x#8 | 46.3x#8 | — | 306.4%#2 | -1407.5%#10 | 0.1%#5 | — | — | 7.8%#1 | — |
| NGNE | $553M#1 | — | 2.5x#6 | — | -100.0%#10 | -20.2%#10 | — | -41.6%#12 | — | — | — | — |
| IMMX | $550M#2 | — | 2.4x#5 | — | — | -36.0%#12 | — | -12.8%#10 | — | — | — | — |
| PBYI | $538M#3 | 20.5x#3 | 3.9x#10 | 2.4x#4 | -0.9%#7 | 2.8%#8 | 16.3%#2 | 22.5%#3 | — | — | — | — |
| ARVN | $513M#4 | 30.2x#4 | 0.9x#1 | 2.0x#3 | -0.3%#6 | 59.3%#4 | -45.1%#6 | -14.4%#11 | -25.3%#4 | — | — | — |
| FBIOP | — | 5.5x#2 | — | — | 9.7%#5 | 76.2%#3 | -111.0%#7 | 22.5%#2 | — | — | — | — |
| CTMX | $511M#5 | — | 1.7x#3 | 6.7x#6 | -44.8%#9 | -154.5%#15 | -29.3%#5 | -5.7%#6 | -7.8%#2 | — | — | — |
| GYRE | $508M#6 | — | 4.7x#11 | 4.4x#5 | 10.2%#4 | -44.8%#13 | 9.9%#3 | 9.2%#4 | 12.0%#1 | 3#2 | — | 8.9%#1 |
| DMAC | $500M#8 | — | 13.0x#12 | 1000.3x#10 | — | -34.0%#11 | -6879.4%#11 | -85.5%#13 | — | — | — | — |
| OVID | $495M#9 | — | 2.4x#4 | 68.3x#9 | 1181.3%#1 | 34.1%#5 | -585.2%#9 | -8.3%#7 | — | — | — | — |
| AQST | $490M#10 | — | — | 11.0x#7 | -22.6%#8 | -89.8%#14 | -159.5%#8 | — | — | — | — | — |
| EOLS | $485M#11 | — | — | 1.6x#2 | 11.6%#3 | -2.4%#9 | -11.0%#4 | — | -40.5%#5 | 4#1 | — | — |
| FTH | $482M#12 | — | 2.8x#7 | — | — | 30.1%#6 | — | -12.2%#9 | -15.2%#3 | — | — | — |
| MNPR | $474M#13 | — | 3.6x#9 | — | — | 12.0%#7 | — | -10.5%#8 | — | — | — | — |
| CRMD | $444M#14 | 2.6x#1 | 1.0x#2 | 1.4x#1 | 617.0%#2 | 1009.4%#1 | 48.2%#1 | 35.4%#1 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-01。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议